ELErin Lambourne

Erin Lambourne

*This is an algorithmically generated author record based on publicly available information.

Erin Lambourne has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    First‐in‐human safety, tolerability, pharmacokinetics and pilot food‐effect study of the candidate antimalarial compound MMV367

    by Andrea Kuemmerle, Nand Singh, Denis Gossen, Annick Janin, Raman Sharma, Anthony Cahn, Rachel A. Gibson, Somasekhara R. Menakuru, Erin Lambourne, Tom Dove, et al.

    Aim: To evaluate the safety, tolerability and pharmacokinetics in healthy participants of orally administered MMV367 (GSK3772701), a novel antimalarial interfering with Plasmodium falciparum acyl coenzyme A synthetase 10/11 function.Methods: This first‐in‐human study enrolled 47 healthy male and female participants. Part 1 was a randomised, double‐blind, placebo‐controlled study in which four sequential fasted cohorts received MMV367 single ascending doses (100, 300, 750 and 1500 mg) or placebo (six active, two placebo per cohort). Part 2 was a randomised, open‐label crossover (fed‐fasted) pilot food‐effect study of MMV367 440 mg (n = 8). In Part 3 MMV367 400 mg was administered once daily for 3 days in a single cohort (six active, two placebo).Results: Treatment‐emergent adverse events (TEAEs) occurred in 36.8% (14/38) of participants receiving MMV367 vs 44.4% (4/9) with placebo. There were two MMV367‐related TEAEs, and no serious or severe TEAEs or clinically relevant changes in electrocardiograms, vital signs or laboratory tests. In Part 1 (fasted), maximum plasma concentrations occurred between 2.0 and 5.0 h post dose, with a geometric mean half‐life of 16.5‐18.4 h. Approximate dose proportionality was demonstrated across the dose range (100‐1500 mg). In Part 2, MMV367 relative bioavailability (fed vs fasted) was 161.4% (90% confidence interval 148.3, 175.6) for maximum observed concentration (Cmax), 130.4% (122.2, 139.1) for the area under the curve (AUC) until the last measurable concentration and 132.9% (124.1, 142.3) for AUC extrapolated to infinity. In Part 3, geometric mean day 1:3 exposure ratios (geometric co‐efficient of variability) were 1.9 (4.9%) for Cmax and 2.1 (7.7%) for the AUC for the defined interval between doses after once‐daily dosing for 3 days.Conclusions: MMV367 demonstrated acceptable safety, tolerability and pharmacokinetic profiles supporting further development as an antimalarial drug.

  • Open Access

    First‐in‐human safety, tolerability, pharmacokinetics and pilot food‐effect study of the candidate antimalarial compound MMV367

    by Andrea Kuemmerle, Nand Singh, Denis Gossen, Annick Janin, Raman Sharma, Anthony Cahn, Rachel A. Gibson, Somasekhara R. Menakuru, Erin Lambourne, Tom Dove, et al.

    Aim: To evaluate the safety, tolerability and pharmacokinetics in healthy participants of orally administered MMV367 (GSK3772701), a novel antimalarial interfering with Plasmodium falciparum acyl coenzyme A synthetase 10/11 function.Methods: This first‐in‐human study enrolled 47 healthy male and female participants. Part 1 was a randomised, double‐blind, placebo‐controlled study in which four sequential fasted cohorts received MMV367 single ascending doses (100, 300, 750 and 1500 mg) or placebo (six active, two placebo per cohort). Part 2 was a randomised, open‐label crossover (fed‐fasted) pilot food‐effect study of MMV367 440 mg (n = 8). In Part 3 MMV367 400 mg was administered once daily for 3 days in a single cohort (six active, two placebo).Results: Treatment‐emergent adverse events (TEAEs) occurred in 36.8% (14/38) of participants receiving MMV367 vs 44.4% (4/9) with placebo. There were two MMV367‐related TEAEs, and no serious or severe TEAEs or clinically relevant changes in electrocardiograms, vital signs or laboratory tests. In Part 1 (fasted), maximum plasma concentrations occurred between 2.0 and 5.0 h post dose, with a geometric mean half‐life of 16.5‐18.4 h. Approximate dose proportionality was demonstrated across the dose range (100‐1500 mg). In Part 2, MMV367 relative bioavailability (fed vs fasted) was 161.4% (90% confidence interval 148.3, 175.6) for maximum observed concentration (Cmax), 130.4% (122.2, 139.1) for the area under the curve (AUC) until the last measurable concentration and 132.9% (124.1, 142.3) for AUC extrapolated to infinity. In Part 3, geometric mean day 1:3 exposure ratios (geometric co‐efficient of variability) were 1.9 (4.9%) for Cmax and 2.1 (7.7%) for the AUC for the defined interval between doses after once‐daily dosing for 3 days.Conclusions: MMV367 demonstrated acceptable safety, tolerability and pharmacokinetic profiles supporting further development as an antimalarial drug.